T 2643/16 (Sofosbuvir/GILEAD) of 16.02.2023
- European Case Law Identifier
- ECLI:EP:BA:2023:T264316.20230216
- Date of decision
- 16 February 2023
- Case number
- T 2643/16
- Petition for review of
- -
- Application number
- 08732818.3
- IPC class
- A61K 31/7064A61K 31/7076
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- T 2643/16 Sofosbuvir/GILEAD 2024-06-03
- Abstracts for this decision
- -
- Application title
- NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
- Applicant name
- Gilead Pharmasset LLC
- Opponent name
- MEDECINS DU MONDE
Fleischer, Holm Herbert
ELLIS IP LTD
Pharmaceutical Works POLPHARMA
Generics [UK] Ltd (trading as Mylan)
Teva Pharmaceutical Industries Ltd.
I P S Intellectual Property Services
STADA Arzneimittel AG
ZBM Patents - Zea, Barlocci & Markvardsen
Actavis Group PTC ehf - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(c)European Patent Convention Art 56European Patent Convention Art 87
- Keywords
- Added subject-matter - disclosure of individual diastereomers (no)
Inventive step - ex post facto analysis - Catchword
- -
Order
For these reasons it is decided that:
- The ground for opposition of Article 100(c) EPC prejudices the maintenance of the patent as granted.
- Each of auxiliary requests 3 (filed as auxiliary request 2 with the appellant-patent proprietor's statement of grounds of appeal), 4, 6, 8 and 10 add subject-matter, contrary to Article 123(2) EPC.
- D1 and D2 disclose the same invention in an enabling manner as claimed in auxiliary request 1.
- The subject-matter of auxiliary request 1 is inventive starting from any of documents D4, D7, D10, D12 and D33, excluding any combination with documents published after the earliest priority date of the patent.
- The appeal proceedings are stayed until the decisions in referral cases G 2/21, G 1/22 and G 2/22 have been issued.